시장보고서
상품코드
1193118

항콕시듐제 시장 : 약물 클래스별(이오노포어, 합성약), 약물 작용별(Coccidiostatic, Coccidiocidal), 동물 유형별(가금류, 소, 기타) - 세계 기회 분석 및 산업 예측(2021-2031년)

Anticoccidial Drugs Market By Drug Class (Ionophore, Synthetic Drugs), By Drug Action (Coccidiostatic, Coccidiocidal), By Animal Type (Poultry, Cattle, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031

발행일: | 리서치사: Allied Market Research | 페이지 정보: 영문 220 Pages | 배송안내 : 2-3일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

항콕시듐제의 세계 시장은 2021년에 1억 7130만 달러로 평가되고, 2022년부터 2031년에 걸쳐 CAGR 4.2%로 성장했으며, 2031년에는 2억 5780만 달러에 달할 것으로 예측되고 있습니다 .

콕시듐증은 가금류에서 가장 흔한 질병 중 하나이며 Eimeria 속의 원생 동물 기생충에 의해 유발됩니다. 이 기생충은 의무적인 세포 내 기생충이며, 유성기와 무성기를 포함한 복잡한 수명주기를 가지고 있습니다. 이 기생충은 장에 기생하여 다른 질병 (괴사성 장염)을 일으키기 쉽고이 기관의 영양 흡수 능력을 저하시킵니다. 이 질병은 곤충과 들새와 같은 기계적 매개로 감염됩니다. 그러나 야생 조류의 경우 계란 (오시스트)은 기계적으로 수송되지만 이러한 기생충은 숙주 특이적이기 때문에 야생 조류는 생물학적 저장소의 역할을 수행하지 않습니다. 따라서이 질병은 항 콕시듐 약물의 도움으로 제어 할 수 있습니다. 육계의 수명주기가 짧기 때문에 콕시듐과 같은 기생충을 죽이는 약물을 사용하면 장내 에이메리아를 완전히 제거 할 수 있습니다.

항콕시듐제 시장의 성장은 첨단 항콕시듐제 개발의 증가, 콕시듐증 및 그 치료법에 대한 계몽을 위한 정부 노력의 증가에 의해 추진되고 있습니다. 또한 고기, 우유 등 동물성 단백질 식품의 수요 높이, 항콕시듐제 개발 위탁 증가, 제약·바이오테크놀로지 산업의 발전도 시장 성장을 뒷받침하고 있습니다. 그러나 가축에 대한 항 콕시듐 약물의 사용을 제한하는 정부의 엄격한 규제와 백신과 생약과 같은 대체 의약품의 사용은이 시장의 성장을 방해 할 것으로 예상됩니다. 반대로, 저렴한 가격으로 입수할 수 있는 신제품에 대한 인지도의 향상은 시장에 유리한 기회를 창출할 것으로 예상됩니다.

목차

제1장 소개

제2장 주요 요약

제3장 시장 개요

  • 시장의 정의와 범위
  • 주요 조사 결과
    • 주요 투자 포켓
  • Porter's Five Forces 분석
  • 시장 역학
    • 촉진 요인
    • 억제 요인
    • 기회
  • COVID-19의 시장에의 영향도 분석

제4장 항콕시듐제 시장 : 약효 분류별

  • 개요
    • 시장 규모 및 예측
  • 이오노포어
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 점유율 분석 : 국가별
  • 합성의약품
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 점유율 분석 : 국가별

제5장 항콕시듐제 시장 : 약효별

  • 개요
    • 시장 규모 및 예측
  • Coccidiostatic
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모 및 예측 : 지역별
    • 시장 점유율 분석 : 국가별
  • Coccidiocidal
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 점유율 분석 : 국가별

제6장 항콕시듐제 시장 : 동물 유형별

  • 개요
    • 시장 규모 및 예측
  • 가금류
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모 및 예측 : 지역별
    • 시장 점유율 분석 : 국가별
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 점유율 분석 : 국가별
  • 기타
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 점유율 분석 : 국가별

제7장 항콕시듐제 시장 : 지역별

  • 개요
    • 시장 규모·예측
  • 북미
    • 주요 동향과 기회
    • 북미 시장 규모·예측 : 약물 클래스별
    • 북미 시장 규모·예측 : 약물 작용별
    • 북미 시장 규모·예측 : 동물 유형별
    • 북미 시장 규모·예측 : 국가별
      • 미국
      • 캐나다
      • 멕시코
  • 유럽
    • 주요 동향과 기회
    • 유럽 시장 규모·예측 : 약물 클래스별
    • 유럽 시장 규모·예측 : 약물 작용별
    • 유럽 시장 규모·예측 : 동물 유형별
    • 유럽 시장 규모·예측 : 국가별
      • 독일
      • 프랑스
      • 영국
      • 이탈리아
      • 스페인
      • 기타 유럽
  • 아시아태평양
    • 주요 동향과 기회
    • 아시아태평양의 시장 규모·예측 : 약물 클래스별
    • 아시아태평양의 시장 규모·예측 : 약물 작용별
    • 아시아태평양의 시장 규모·예측 : 동물 유형별
    • 아시아태평양의 시장 규모·예측 : 국가별
      • 일본
      • 중국
      • 호주
      • 인도
      • 한국
      • 기타 아시아태평양
  • LAMEA
    • 주요 동향과 기회
    • LAMEA의 시장 규모·예측 : 약물 클래스별
    • LAMEA의 시장 규모·예측 : 약물작용별
    • LAMEA의 시장 규모·예측 : 동물 유형별
    • LAMEA의 시장 규모·예측 : 국가별
      • 브라질
      • 사우디아라비아
      • 남아프리카 공화국
      • 기타 LAMEA 지역

제8장 기업 정세

  • 소개
  • 주요 성공 전략
  • 주요 10개사의 제품 매핑
  • 톱 기업의 포지셔닝, 2021년
  • 경쟁 대시보드
  • 경쟁 히트맵
  • 주요 발전

제9장 기업 프로필

  • boehringer ingelheim animal health-us
  • Ceva sante animale
  • Huvepharma EOOD
  • Merck & Co., Inc
  • Venkateshwara hatcheries Private Limited
  • Dosh Pharmaceuticals
  • Vetoquinol SA
  • Virbac SA
  • Zoetis Inc
  • Bayer AG
ksm 23.03.27

The global anticoccidial drugs market was valued at $171.3 million in 2021, and is projected to reach $257.8 million by 2031, registering a CAGR of 4.2% from 2022 to 2031.

Coccidiosis is one of the most common diseases in the poultry population is caused by protozoan parasites of the genus Eimeria. These are obligated intracellular parasites with complex life cycles including sexual and asexual stages. These parasites affect the intestine making it prone to other diseases (necrotic enteritis) and reducing the ability of this organ to absorb nutrients. This disease is transmitted or spread by mechanical carriers such as insects and wild birds. However, the Eimeria eggs (oocysts) can be mechanically transported by wild birds, these parasites are host-specific and thus wild birds do not serve as a biological reservoir. Hence, this disease can be controlled by the help of anticoccidial drugs. The short life cycle of a broiler eliminates Eimeria completely from the gut by using the drugs like coccidicides that kill the parasites.

The growth of the anticoccidial drugs market is driven by the increase in development of advanced anticoccidial drugs, increase in the government initiatives for the awareness about the coccidiosis and its medications. Moreover, the high demand of animal protein food such as meat, milk, and others, increase in the outsourcing of the development of the anticoccidial drugs, and the development in the pharmaceutical and biotechnology industries also helps in the growth of the market. However, a stringent government regulations that restricts the usage of anticoccidial drugs in livestock and the use of alternative medicines such as vaccines and herbal medicines to treat coccidiosis are expected to hinder the growth of this market. Conversely, the rise in awareness about the new products available at affordable rates is expected to create lucrative opportunities for the market.

The global anticoccidial drugs market is segmented based on drug class, drug action, animal type, and region. On the basis of drug class, the market is bifurcated into ionophore and synthetic drugs. On the basis of drug action, the market is classified into coccidiostatic and coccidiocidal. On the basis of animal type, the market is classified into poultry, cattle and others. Region wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The key market players operating in this market include Bayer AG, Boehringer Ingelheim International GmbH, Ceva sante animale, Dosh Pharmaceuticals Private Limited, Huvepharma EOOD, Merck & Co., Inc., Venkateshwara hatcheries Private Limited, Vetoquinol SA, Virbac SA, Zoetis Inc.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the anticoccidial drugs market analysis from 2021 to 2031 to identify the prevailing anticoccidial drugs market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the anticoccidial drugs market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global anticoccidial drugs market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug Class

  • Ionophore
  • Synthetic Drugs

By Drug Action

  • Coccidiostatic
  • Coccidiocidal

By Animal Type

  • Poultry
  • Cattle
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • boehringer ingelheim animal health - us
    • Ceva sante animale
    • Huvepharma EOOD
    • Merck & Co., Inc
    • Venkateshwara hatcheries Private Limited
    • Dosh Pharmaceuticals
    • Vetoquinol SA
    • Virbac SA
    • Zoetis Inc
    • Bayer AG

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Market dynamics
    • 3.4.1.Drivers
    • 3.4.2.Restraints
    • 3.4.3.Opportunities
  • 3.5.COVID-19 Impact Analysis on the market

CHAPTER 4: ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Ionophore
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market share analysis by country
  • 4.3 Synthetic Drugs
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market share analysis by country

CHAPTER 5: ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Coccidiostatic
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market share analysis by country
  • 5.3 Coccidiocidal
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market share analysis by country

CHAPTER 6: ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Poultry
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market share analysis by country
  • 6.3 Cattle
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market share analysis by country
  • 6.4 Others
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market share analysis by country

CHAPTER 7: ANTICOCCIDIAL DRUGS MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Drug Class
    • 7.2.3 North America Market size and forecast, by Drug Action
    • 7.2.4 North America Market size and forecast, by Animal Type
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Key market trends, growth factors and opportunities
      • 7.2.5.1.2 Market size and forecast, by Drug Class
      • 7.2.5.1.3 Market size and forecast, by Drug Action
      • 7.2.5.1.4 Market size and forecast, by Animal Type
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Key market trends, growth factors and opportunities
      • 7.2.5.2.2 Market size and forecast, by Drug Class
      • 7.2.5.2.3 Market size and forecast, by Drug Action
      • 7.2.5.2.4 Market size and forecast, by Animal Type
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Key market trends, growth factors and opportunities
      • 7.2.5.3.2 Market size and forecast, by Drug Class
      • 7.2.5.3.3 Market size and forecast, by Drug Action
      • 7.2.5.3.4 Market size and forecast, by Animal Type
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Drug Class
    • 7.3.3 Europe Market size and forecast, by Drug Action
    • 7.3.4 Europe Market size and forecast, by Animal Type
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 Germany
      • 7.3.5.1.1 Key market trends, growth factors and opportunities
      • 7.3.5.1.2 Market size and forecast, by Drug Class
      • 7.3.5.1.3 Market size and forecast, by Drug Action
      • 7.3.5.1.4 Market size and forecast, by Animal Type
      • 7.3.5.2 France
      • 7.3.5.2.1 Key market trends, growth factors and opportunities
      • 7.3.5.2.2 Market size and forecast, by Drug Class
      • 7.3.5.2.3 Market size and forecast, by Drug Action
      • 7.3.5.2.4 Market size and forecast, by Animal Type
      • 7.3.5.3 UK
      • 7.3.5.3.1 Key market trends, growth factors and opportunities
      • 7.3.5.3.2 Market size and forecast, by Drug Class
      • 7.3.5.3.3 Market size and forecast, by Drug Action
      • 7.3.5.3.4 Market size and forecast, by Animal Type
      • 7.3.5.4 Italy
      • 7.3.5.4.1 Key market trends, growth factors and opportunities
      • 7.3.5.4.2 Market size and forecast, by Drug Class
      • 7.3.5.4.3 Market size and forecast, by Drug Action
      • 7.3.5.4.4 Market size and forecast, by Animal Type
      • 7.3.5.5 Spain
      • 7.3.5.5.1 Key market trends, growth factors and opportunities
      • 7.3.5.5.2 Market size and forecast, by Drug Class
      • 7.3.5.5.3 Market size and forecast, by Drug Action
      • 7.3.5.5.4 Market size and forecast, by Animal Type
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Key market trends, growth factors and opportunities
      • 7.3.5.6.2 Market size and forecast, by Drug Class
      • 7.3.5.6.3 Market size and forecast, by Drug Action
      • 7.3.5.6.4 Market size and forecast, by Animal Type
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Drug Class
    • 7.4.3 Asia-Pacific Market size and forecast, by Drug Action
    • 7.4.4 Asia-Pacific Market size and forecast, by Animal Type
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 Japan
      • 7.4.5.1.1 Key market trends, growth factors and opportunities
      • 7.4.5.1.2 Market size and forecast, by Drug Class
      • 7.4.5.1.3 Market size and forecast, by Drug Action
      • 7.4.5.1.4 Market size and forecast, by Animal Type
      • 7.4.5.2 China
      • 7.4.5.2.1 Key market trends, growth factors and opportunities
      • 7.4.5.2.2 Market size and forecast, by Drug Class
      • 7.4.5.2.3 Market size and forecast, by Drug Action
      • 7.4.5.2.4 Market size and forecast, by Animal Type
      • 7.4.5.3 Australia
      • 7.4.5.3.1 Key market trends, growth factors and opportunities
      • 7.4.5.3.2 Market size and forecast, by Drug Class
      • 7.4.5.3.3 Market size and forecast, by Drug Action
      • 7.4.5.3.4 Market size and forecast, by Animal Type
      • 7.4.5.4 India
      • 7.4.5.4.1 Key market trends, growth factors and opportunities
      • 7.4.5.4.2 Market size and forecast, by Drug Class
      • 7.4.5.4.3 Market size and forecast, by Drug Action
      • 7.4.5.4.4 Market size and forecast, by Animal Type
      • 7.4.5.5 South Korea
      • 7.4.5.5.1 Key market trends, growth factors and opportunities
      • 7.4.5.5.2 Market size and forecast, by Drug Class
      • 7.4.5.5.3 Market size and forecast, by Drug Action
      • 7.4.5.5.4 Market size and forecast, by Animal Type
      • 7.4.5.6 Rest of Asia-Pacific
      • 7.4.5.6.1 Key market trends, growth factors and opportunities
      • 7.4.5.6.2 Market size and forecast, by Drug Class
      • 7.4.5.6.3 Market size and forecast, by Drug Action
      • 7.4.5.6.4 Market size and forecast, by Animal Type
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Drug Class
    • 7.5.3 LAMEA Market size and forecast, by Drug Action
    • 7.5.4 LAMEA Market size and forecast, by Animal Type
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Key market trends, growth factors and opportunities
      • 7.5.5.1.2 Market size and forecast, by Drug Class
      • 7.5.5.1.3 Market size and forecast, by Drug Action
      • 7.5.5.1.4 Market size and forecast, by Animal Type
      • 7.5.5.2 Saudi Arabia
      • 7.5.5.2.1 Key market trends, growth factors and opportunities
      • 7.5.5.2.2 Market size and forecast, by Drug Class
      • 7.5.5.2.3 Market size and forecast, by Drug Action
      • 7.5.5.2.4 Market size and forecast, by Animal Type
      • 7.5.5.3 South Africa
      • 7.5.5.3.1 Key market trends, growth factors and opportunities
      • 7.5.5.3.2 Market size and forecast, by Drug Class
      • 7.5.5.3.3 Market size and forecast, by Drug Action
      • 7.5.5.3.4 Market size and forecast, by Animal Type
      • 7.5.5.4 Rest of LAMEA
      • 7.5.5.4.1 Key market trends, growth factors and opportunities
      • 7.5.5.4.2 Market size and forecast, by Drug Class
      • 7.5.5.4.3 Market size and forecast, by Drug Action
      • 7.5.5.4.4 Market size and forecast, by Animal Type

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Top player positioning, 2021
  • 8.5. Competitive Dashboard
  • 8.6. Competitive Heatmap
  • 8.7. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 boehringer ingelheim animal health - us
    • 9.1.1 Company overview
    • 9.1.2 Key Executives
    • 9.1.3 Company snapshot
    • 9.1.4 Operating business segments
    • 9.1.5 Product portfolio
    • 9.1.6 Business performance
    • 9.1.7 Key strategic moves and developments
  • 9.2 Ceva sante animale
    • 9.2.1 Company overview
    • 9.2.2 Key Executives
    • 9.2.3 Company snapshot
    • 9.2.4 Operating business segments
    • 9.2.5 Product portfolio
    • 9.2.6 Business performance
    • 9.2.7 Key strategic moves and developments
  • 9.3 Huvepharma EOOD
    • 9.3.1 Company overview
    • 9.3.2 Key Executives
    • 9.3.3 Company snapshot
    • 9.3.4 Operating business segments
    • 9.3.5 Product portfolio
    • 9.3.6 Business performance
    • 9.3.7 Key strategic moves and developments
  • 9.4 Merck & Co., Inc
    • 9.4.1 Company overview
    • 9.4.2 Key Executives
    • 9.4.3 Company snapshot
    • 9.4.4 Operating business segments
    • 9.4.5 Product portfolio
    • 9.4.6 Business performance
    • 9.4.7 Key strategic moves and developments
  • 9.5 Venkateshwara hatcheries Private Limited
    • 9.5.1 Company overview
    • 9.5.2 Key Executives
    • 9.5.3 Company snapshot
    • 9.5.4 Operating business segments
    • 9.5.5 Product portfolio
    • 9.5.6 Business performance
    • 9.5.7 Key strategic moves and developments
  • 9.6 Dosh Pharmaceuticals
    • 9.6.1 Company overview
    • 9.6.2 Key Executives
    • 9.6.3 Company snapshot
    • 9.6.4 Operating business segments
    • 9.6.5 Product portfolio
    • 9.6.6 Business performance
    • 9.6.7 Key strategic moves and developments
  • 9.7 Vetoquinol SA
    • 9.7.1 Company overview
    • 9.7.2 Key Executives
    • 9.7.3 Company snapshot
    • 9.7.4 Operating business segments
    • 9.7.5 Product portfolio
    • 9.7.6 Business performance
    • 9.7.7 Key strategic moves and developments
  • 9.8 Virbac SA
    • 9.8.1 Company overview
    • 9.8.2 Key Executives
    • 9.8.3 Company snapshot
    • 9.8.4 Operating business segments
    • 9.8.5 Product portfolio
    • 9.8.6 Business performance
    • 9.8.7 Key strategic moves and developments
  • 9.9 Zoetis Inc
    • 9.9.1 Company overview
    • 9.9.2 Key Executives
    • 9.9.3 Company snapshot
    • 9.9.4 Operating business segments
    • 9.9.5 Product portfolio
    • 9.9.6 Business performance
    • 9.9.7 Key strategic moves and developments
  • 9.10 Bayer AG
    • 9.10.1 Company overview
    • 9.10.2 Key Executives
    • 9.10.3 Company snapshot
    • 9.10.4 Operating business segments
    • 9.10.5 Product portfolio
    • 9.10.6 Business performance
    • 9.10.7 Key strategic moves and developments
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제